TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
XBIT

XBiotech Inc

Healthcare · Biotechnology

2.20$ +0.5% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns XBiotech Inc (XBIT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.9% of the shares are freely tradable; institutional investors hold 6.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 6.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 24.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 74.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 1.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 31Mio.

Largest Shareholders

Institutions

Institutions XBIT
Name Stake (%) Shares Change (%) Date
BlackRock Inc 0.96 293,104 +1.5 03/31/2026
Geode Capital Management, LLC 0.76 231,020 +4.5 03/31/2026
Vanguard Capital Management, LLC 0.66 200,971 +0.0 03/31/2026
RBF LLC 0.65 198,501 -50.0 03/31/2026
Morgan Stanley - Brokerage Accounts 0.54 165,554 +1.3 03/31/2026
Bridgeway Capital Management, LLC 0.32 98,447 +9.9 03/31/2026
Vanguard Fiduciary Trust Co 0.30 91,576 +0.0 03/31/2026
Millennium Management LLC 0.26 79,330 -24.8 06/30/2026

Funds

Funds XBIT
Name Stake (%) Shares Change (%) Date
Vanguard Institutional Extnd Mkt Idx Tr 0.66 200,182 +0.0 07/31/2026
Fidelity Extended Market Index 0.31 94,737 -0.2 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?